Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials

Emilio Bria; Luisa Carbognin; Jenny Furlanetto; Sara Pilotto; Maria Bonomi; Valentina Guarneri; Cecilia Vicentini; Matteo Brunelli; Rolando Nortilli; Francesca Pellini; Isabella Sperduti; Diana Giannarelli; Giovanni Paolo Pollini; Pierfranco Conte; Giampaolo Tortora

doi:10.1016/j.ctrv.2014.05.001

Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials

Emilio Bria, Luisa Carbognin, Jenny Furlanetto, Sara Pilotto, Maria Bonomi, Valentina Guarneri, Cecilia Vicentini, Matteo Brunelli, Rolando Nortilli, Francesca Pellini, Isabella Sperduti, Diana Giannarelli, Giovanni Paolo Pollini, Pierfranco Conte, Giampaolo Tortora

Research output: Contribution to journal › Article › peer-review

Abstract

The role of the dual HER2 inhibition, and the best chemotherapy backbone for neoadjuvant chemotherapy still represent an issue for clinical practice.A literature-based meta-analysis exploring single versus dual HER2 inhibition in terms of pathological complete response (pCR, breast plus axilla) rate and testing the interaction according to the chemotherapy (anthracyclines-taxanes or taxanes) was conducted. In addition, an event-based pooled analysis by extracting activity and safety events and deriving 95% confidence intervals (CI) was accomplished.Fourteen trials (4149 patients) were identified, with 6 trials (1820 patients) included in the meta-analysis and 31 arms (14 trials, 3580 patients) in the event-based pooled analysis. The dual HER2 inhibition significantly improves pCR rate, in the range of 16-19%, regardless of the chemotherapy backbone (relative risk 1.37, 95% CI 1.23-1.53, p

Original language	English
Pages (from-to)	847-856
Number of pages	10
Journal	Cancer Treatment Reviews
Volume	40
Issue number	7
DOIs	https://doi.org/10.1016/j.ctrv.2014.05.001
Publication status	Published - 2014

Keywords

Breast cancer
HER2-positive
Meta-analysis
Neoadjuvant
Trastuzumab

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2014.05.001

Fingerprint

Dive into the research topics of 'Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials'. Together they form a unique fingerprint.

Cite this

Bria, E., Carbognin, L., Furlanetto, J., Pilotto, S., Bonomi, M., Guarneri, V., Vicentini, C., Brunelli, M., Nortilli, R., Pellini, F., Sperduti, I., Giannarelli, D., Pollini, G. P., Conte, P., & Tortora, G. (2014). Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials. Cancer Treatment Reviews, 40(7), 847-856. https://doi.org/10.1016/j.ctrv.2014.05.001

Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer : Sensitivity analysis of randomized trials. / Bria, Emilio; Carbognin, Luisa; Furlanetto, Jenny; Pilotto, Sara; Bonomi, Maria; Guarneri, Valentina; Vicentini, Cecilia; Brunelli, Matteo; Nortilli, Rolando; Pellini, Francesca; Sperduti, Isabella ; Giannarelli, Diana; Pollini, Giovanni Paolo; Conte, Pierfranco; Tortora, Giampaolo.

In: Cancer Treatment Reviews, Vol. 40, No. 7, 2014, p. 847-856.

Research output: Contribution to journal › Article › peer-review

Bria, E, Carbognin, L, Furlanetto, J, Pilotto, S, Bonomi, M, Guarneri, V, Vicentini, C, Brunelli, M, Nortilli, R, Pellini, F, Sperduti, I , Giannarelli, D, Pollini, GP, Conte, P & Tortora, G 2014, 'Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials', Cancer Treatment Reviews, vol. 40, no. 7, pp. 847-856. https://doi.org/10.1016/j.ctrv.2014.05.001

Bria, Emilio ; Carbognin, Luisa ; Furlanetto, Jenny ; Pilotto, Sara ; Bonomi, Maria ; Guarneri, Valentina ; Vicentini, Cecilia ; Brunelli, Matteo ; Nortilli, Rolando ; Pellini, Francesca ; Sperduti, Isabella ; Giannarelli, Diana ; Pollini, Giovanni Paolo ; Conte, Pierfranco ; Tortora, Giampaolo. / Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer : Sensitivity analysis of randomized trials. In: Cancer Treatment Reviews. 2014 ; Vol. 40, No. 7. pp. 847-856.

@article{aafcb9014e4e4411a55444a3bf8ba21c,

title = "Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials",

abstract = "The role of the dual HER2 inhibition, and the best chemotherapy backbone for neoadjuvant chemotherapy still represent an issue for clinical practice.A literature-based meta-analysis exploring single versus dual HER2 inhibition in terms of pathological complete response (pCR, breast plus axilla) rate and testing the interaction according to the chemotherapy (anthracyclines-taxanes or taxanes) was conducted. In addition, an event-based pooled analysis by extracting activity and safety events and deriving 95% confidence intervals (CI) was accomplished.Fourteen trials (4149 patients) were identified, with 6 trials (1820 patients) included in the meta-analysis and 31 arms (14 trials, 3580 patients) in the event-based pooled analysis. The dual HER2 inhibition significantly improves pCR rate, in the range of 16-19%, regardless of the chemotherapy backbone (relative risk 1.37, 95% CI 1.23-1.53, p",

keywords = "Breast cancer, HER2-positive, Meta-analysis, Neoadjuvant, Trastuzumab",

author = "Emilio Bria and Luisa Carbognin and Jenny Furlanetto and Sara Pilotto and Maria Bonomi and Valentina Guarneri and Cecilia Vicentini and Matteo Brunelli and Rolando Nortilli and Francesca Pellini and Isabella Sperduti and Diana Giannarelli and Pollini, {Giovanni Paolo} and Pierfranco Conte and Giampaolo Tortora",

year = "2014",

doi = "10.1016/j.ctrv.2014.05.001",

language = "English",

volume = "40",

pages = "847--856",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "7",

}

TY - JOUR

T1 - Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer

T2 - Sensitivity analysis of randomized trials

AU - Bria, Emilio

AU - Carbognin, Luisa

AU - Furlanetto, Jenny

AU - Pilotto, Sara

AU - Bonomi, Maria

AU - Guarneri, Valentina

AU - Vicentini, Cecilia

AU - Brunelli, Matteo

AU - Nortilli, Rolando

AU - Pellini, Francesca

AU - Sperduti, Isabella

AU - Giannarelli, Diana

AU - Pollini, Giovanni Paolo

AU - Conte, Pierfranco

AU - Tortora, Giampaolo

PY - 2014

Y1 - 2014

N2 - The role of the dual HER2 inhibition, and the best chemotherapy backbone for neoadjuvant chemotherapy still represent an issue for clinical practice.A literature-based meta-analysis exploring single versus dual HER2 inhibition in terms of pathological complete response (pCR, breast plus axilla) rate and testing the interaction according to the chemotherapy (anthracyclines-taxanes or taxanes) was conducted. In addition, an event-based pooled analysis by extracting activity and safety events and deriving 95% confidence intervals (CI) was accomplished.Fourteen trials (4149 patients) were identified, with 6 trials (1820 patients) included in the meta-analysis and 31 arms (14 trials, 3580 patients) in the event-based pooled analysis. The dual HER2 inhibition significantly improves pCR rate, in the range of 16-19%, regardless of the chemotherapy backbone (relative risk 1.37, 95% CI 1.23-1.53, p

AB - The role of the dual HER2 inhibition, and the best chemotherapy backbone for neoadjuvant chemotherapy still represent an issue for clinical practice.A literature-based meta-analysis exploring single versus dual HER2 inhibition in terms of pathological complete response (pCR, breast plus axilla) rate and testing the interaction according to the chemotherapy (anthracyclines-taxanes or taxanes) was conducted. In addition, an event-based pooled analysis by extracting activity and safety events and deriving 95% confidence intervals (CI) was accomplished.Fourteen trials (4149 patients) were identified, with 6 trials (1820 patients) included in the meta-analysis and 31 arms (14 trials, 3580 patients) in the event-based pooled analysis. The dual HER2 inhibition significantly improves pCR rate, in the range of 16-19%, regardless of the chemotherapy backbone (relative risk 1.37, 95% CI 1.23-1.53, p

KW - Breast cancer

KW - HER2-positive

KW - Meta-analysis

KW - Neoadjuvant

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84902011260&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902011260&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2014.05.001

DO - 10.1016/j.ctrv.2014.05.001

M3 - Article

C2 - 24877987

AN - SCOPUS:84902011260

VL - 40

SP - 847

EP - 856

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 7

ER -

Impact of neoadjuvant single or dual HER2 inhibition and chemotherapy backbone upon pathological complete response in operable and locally advanced breast cancer: Sensitivity analysis of randomized trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this